(Q39308716)

English

Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis (English)

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

1 reference

based on heuristic

inferred from title

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

author name string

Minghan Jia

1

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Weijiao Feng

2

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Shiyang Kang

3

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Yaxiong Zhang

4

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Jianfei Shen

5

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Jiaxi He

6

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Long Jiang

7

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Wei Wang

8

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Zhihua Guo

9

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Guilin Peng

10

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Gang Chen

11

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Jianxing He

12

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Wenhua Liang

13

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

publication date

1 March 2015

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Journal of thoracic disease

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

7

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

3

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

455-461

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387409

11 September 2017

Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387409

11 September 2017

Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387409

11 September 2017

Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387409

11 September 2017

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387409

11 September 2017

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387409

11 September 2017

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387409

11 September 2017

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387409

11 September 2017

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387409

11 September 2017

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387409

11 September 2017

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387409

11 September 2017

Inhibitory B7-family molecules in the tumour microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387409

11 September 2017

Checkpoint blockade in cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387409

11 September 2017

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387409

11 September 2017

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387409

11 September 2017

Operating characteristics of a rank correlation test for publication bias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387409

11 September 2017

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387409

21 August 2018

Identifiers

10.3978/J.ISSN.2072-1439.2015.02.06

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39308716&oldid=1819492336"